STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

MG has unveiled the "7 Trophy" sedan at the Bharat Mobility Global Expo 2025. This car is poised to compete with models like the Toyota Camry and the upcoming Skoda Superb in India. The MG 7 ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

JSW MG Motor India has showcased the M9 MPV at the ... Space inside is ample, and the Mifa 9 offers 7- and 8-seater layouts. As with other vehicles in the segment, the Mifa 9 comes very well ...

the MG M9, was also revealed at the Auto Expo 2025 ahead of its debut this year. It will be offered in both 6- and 7-seater configurations and will get plenty of tech inside, including a panoramic ...

According to MG Motor India, the Majestor will be the “tallest, longest, and widest” model in its segment. Judging from the Maxus twin, the new SUV will measure 5,046 mm (198.7 inches ...

The M9 positions MG in the premium electric MPV segment and ... The M9 is available in both 6-seat and 7-seat layout options. Features a minimalist design with sleek LED DRLs, 19-inch alloy ...

MG could also equip the Majestor with additional features over the Gloster in keeping with its more premium billing. The Gloster is offered in both 6- and 7-seater configurations, but it remains ...

JSW MG Motor India has unveiled two new cars at the Bharat Mobility Global Expo 2025. Introducing the MG Cyberster, India’s first all-electric roadster, and the MG M9, the country’s first ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...